1. PI3K/Akt/mTOR
  2. PI4K

PI4K

The phosphatidylinositol 4-kinases (PI4Ks) synthesize phosphatidylinositol 4-phosphate (PI4P), a key member of the phosphoinositide family. PI4P defines the membranes of Golgi and trans-Golgi network (TGN) and regulates trafficking to and from the Golgi.

In mammals there are four different PI4K enzymes, two type II enzymes (PI4KIIα and PI4KIIβ) and two type III enzymes (PI4KIIIα and PI4KIIIβ). PI4KIIIβ plays key roles in mediating lipid transport, cytokinesis, maintaining lysosomal identity, and in tandem with Rab GTPases plays key roles in regulating membrane trafficking. PI4KIIIβ is critical for mediating viral replication of a number of RNA viruses through the generation of PI4P enriched viral replication platforms. Small molecule inhibitors of PI4KIIIβ are potent anti-viral agents. Development of PI4KIIIβ as an effective drug target for anti-viral therapeutics requires the generation of highly potent and specific inhibitors.

PI4K Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-12046
    PIK-93 Inhibitor 99.13%
    PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.
  • HY-15679
    PI4KIII beta inhibitor 3 Inhibitor 98.21%
    PI4KIII beta inhibitor 3 is a novel and high effective PI4KIII beta inhibitor with IC50 of 5.7 nM.
  • HY-100198
    PI4KIIIbeta-IN-10 Inhibitor 98.21%
    PI4KIIIbeta-IN-10 is the most potent PI4KIIIβ inhibitor currently reported, with very minor off-target inhibition of PI4KIIIβ related lipid kinases (IC50 = 3.6 nM).
  • HY-19798
    PI4KIIIbeta-IN-9 Inhibitor
    PI4KIIIβ-IN-9 is a potent PI4KIIIβ inhibitor (IC50 of 7 nM) and is >140-fold selective over PI3Kγ and >20-fold selective over PI3Kδ, and shows no inhibition of vps34 at concentrations up to 20 μM.